结核分枝杆菌对异烟肼与丙硫异烟胺独立耐药及交叉耐药的新突变检测
该研究对206株结核分枝杆菌进行十种药物敏感性试验,并测序katG、ethA、ndh、ethR、mshA、inhA及其启动子。在173株异烟肼耐药且丙硫异烟胺耐药菌株中,katG突变占98.3%,ethA突变占64.2%,inhA或其启动子突变占33.5%。研究发现55个新非同义突变,且20.2%的丙硫异烟胺耐药菌株无已知相关突变。
要点
- 异烟肼耐药且丙硫异烟胺耐药菌株中katG突变率高达98.3%。
- 20.2%的丙硫异烟胺耐药菌株未检出已知耐药相关突变。
- 异烟肼耐药结核中丙硫异烟胺的独立耐药与交叉耐药突变呈高度多样性。
核心结论
- 异烟肼耐药(94.4%为MDR-TB)菌株对丙硫异烟胺的独立耐药和交叉耐药突变呈高度多样性,使用丙硫异烟胺治疗异烟肼耐药结核时需结合表型药敏和基因型诊断。
- 约五分之一的丙硫异烟胺耐药菌株未检出已知相关基因突变,提示存在未发现的耐药机制。
研究设计与样本
- 对206株结核分枝杆菌临床分离株进行十种药物的药敏试验,并测序katG、ethA、ndh、ethR、mshA、inhA及其启动子。
主要发现
- 173株异烟肼耐药且丙硫异烟胺耐药菌株中,katG突变170株(98.3%),ethA突变111株(64.2%),inhA或其启动子突变58株(33.5%),ndh突变5株(2.9%),ethR突变3株(1.7%),mshA突变2株(1.2%)。
- 18株异烟肼耐药但丙硫异烟胺敏感菌株均携带katG突变,其中1株有inhA启动子突变,另1株有ndh突变。
- 5株异烟肼敏感但丙硫异烟胺耐药菌株中,4株有ethA突变,2株有inhA启动子突变。
- 共发现55个新非同义突变,20.2%的丙硫异烟胺耐药菌株无已知突变。
临床怎么用
- 对异烟肼耐药结核患者使用丙硫异烟胺前,应同时进行表型药敏试验和基因型耐药检测。
局限性
- 未明确菌株来源人群的代表性及表型药敏试验的具体方法细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Prothionamide, a structural analogue of isoniazid, is used mainly for treating multidrug-resistant tuberculosis (MDR-TB). Both drugs have a common target InhA, so prothionamide can be ineffective against isoniazid-resistant (INHR) Mycobacterium tuberculosis. We aimed to investigate the prevalence of mutations in katG, ethA, ndh, ethR, mshA, inhA and/or its promoter associated with independent resistance and cross-resistance to INHR and/or prothionamide-resistant (PTOR) M. tuberculosis isolates. METHODS: We sequenced the above genes in 206 M. tuberculosis isolates with susceptibility testing against ten drugs. RESULTS: Of the 173 INHR PTOR isolates, 170 (98.3%) harboured mutations in katG, 111 (64.2%) in ethA, 58 (33.5%) in inhA or its promoter, 5 (2.9%) in ndh, 3 (1.7 %) in ethR and 2 (1.2%) in mshA. Among the 18 INHR PTOS isolates, mutations in katG were found in all of them; one had a mutation in the inhA promoter and another in ndh. Of the five INHS PTOR isolates, four showed mutations in ethA and two in the inhA promoter. Notably, 55 novel non-synonymous mutations were found in them and 20.2% of the PTORM. tuberculosis isolates harboured no known mutations. CONCLUSIONS: This is the first report to investigate cross-resistance between INHR and/or PTOR isolates. Among INHR (94.4% MDR-TB) M. tuberculosis isolates, the high diversity of mutations for independent resistance and cross-resistance with prothionamide highlight the importance of both phenotypic susceptibility and genotypic diagnosis when using it to treat patients with INHR-TB. The high proportion (one-fifth) of PTORM. tuberculosis isolates showed no known mutation related to PTOR genes, so uncovered resistance mechanism(s) of prothionamide exist.
引用
- Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect. 2018. PMID: 30583053. doi:10.1016/j.cmi.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。